Insights

Innovative Pain Products Scilex Pharmaceuticals has a strong portfolio of non-opioid pain management products, including ZTlido, GLOPERBA, and ELYXYB, which are FDA-approved and recently launched. These products offer opportunities to expand sales through pain clinics, hospitals, and primary care providers seeking safer pain relief options.

Pipeline Expansion With promising pipeline candidates like SEMDEXA and SP-103, Scilex is poised to introduce next-generation pain therapies. Business opportunities exist in early-stage clinical markets and specialty pain centers looking to adopt innovative treatment options before competitors.

Strategic Partnerships Recent collaborations, including partnerships with Biconomy and investments in AI and cryptocurrency companies, suggest a readiness to explore new technologies and markets. These initiatives present cross-selling opportunities with digital health solutions and innovative financing models.

Market Presence Having launched ZTlido in 2018 and expanding with GLOPERBA and ELYXYB, Scilex demonstrates a growing market footprint. Building relationships with distributors, pharmacy chains, and healthcare providers can accelerate product adoption and drive revenue growth.

Financial Outlook With revenue estimated between $25 million and $50 million, Scilex is a mid-stage company actively increasing its product offerings. Engaging with this expanding firm offers chances to collaborate on sales channels, co-marketing efforts, and educational initiatives to capitalize on their growth trajectory.

Scilex Pharmaceuticals Tech Stack

Scilex Pharmaceuticals uses 8 technology products and services including Alteryx, IQVIA, parallax.js, and more. Explore Scilex Pharmaceuticals's tech stack below.

  • Alteryx
    Advanced Analytics And Data Science
  • IQVIA
    Health Platform
  • parallax.js
    Javascript Libraries
  • Underscore.js
    Javascript Libraries
  • DocuSign
    Miscellaneous
  • Vimeo
    Video Players
  • Translate WordPress
    Web Platform Extensions
  • Twenty Fourteen
    Web Platform Extensions

Media & News

Scilex Pharmaceuticals's Email Address Formats

Scilex Pharmaceuticals uses at least 2 format(s):
Scilex Pharmaceuticals Email FormatsExamplePercentage
FLast@scilexpharma.comJDoe@scilexpharma.com
95%
Last@scilexpharma.comDoe@scilexpharma.com
4%
FL@scilexpharma.comJD@scilexpharma.com
1%
FLast@scilexholding.comJDoe@scilexholding.com
100%

Frequently Asked Questions

What is Scilex Pharmaceuticals's phone number?

Minus sign iconPlus sign icon
You can contact Scilex Pharmaceuticals's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Scilex Pharmaceuticals's official website and social media links?

Minus sign iconPlus sign icon
Scilex Pharmaceuticals's official website is scilexholding.com and has social profiles on LinkedInCrunchbase.

What is Scilex Pharmaceuticals's NAICS code?

Minus sign iconPlus sign icon
Scilex Pharmaceuticals's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Scilex Pharmaceuticals have currently?

Minus sign iconPlus sign icon
As of December 2025, Scilex Pharmaceuticals has approximately 76 employees across 3 continents, including North AmericaAsiaEurope. Key team members include Head Market Access: B. L.Interim General Counsel And Chief Compliance Officer: S. L.Vice President, Research And Development: K. V.. Explore Scilex Pharmaceuticals's employee directory with LeadIQ.

What industry does Scilex Pharmaceuticals belong to?

Minus sign iconPlus sign icon
Scilex Pharmaceuticals operates in the Pharmaceutical Manufacturing industry.

What technology does Scilex Pharmaceuticals use?

Minus sign iconPlus sign icon
Scilex Pharmaceuticals's tech stack includes AlteryxIQVIAparallax.jsUnderscore.jsDocuSignVimeoTranslate WordPressTwenty Fourteen.

What is Scilex Pharmaceuticals's email format?

Minus sign iconPlus sign icon
Scilex Pharmaceuticals's email format typically follows the pattern of FLast@scilexpharma.com. Find more Scilex Pharmaceuticals email formats with LeadIQ.

When was Scilex Pharmaceuticals founded?

Minus sign iconPlus sign icon
Scilex Pharmaceuticals was founded in 2019.

Scilex Pharmaceuticals

Pharmaceutical ManufacturingCalifornia, United States51-200 Employees

SCILEX HOLDING COMPANY (Nasdaq: SCLX, “Scilex”), is dedicated to the development and commercialization of non-opioid pain management products. We are uncompromising in our focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life.

The company’s lead product ZTlido® (lidocaine topical system) 1.8%, is a marketed prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with Post-Herpetic Neuralgia (PHN), which is a form of post-shingles nerve pain. ZTlido® possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief. Click here for ZTLido’s Important Safety Information and US Prescribing Information.

We have acquired two FDA approved non-opioid pain products, GLOPERBA® and ELYXYB®. GLOPERBA® is indicated for the prophylaxis of gout flares in adults. Elyxyb is indicated for the acute treatment of migraine with or without aura in adults. We launched ELYXYB® in the U.S. in 2023 and launched and began commercializing GLOPERBA® in 2024.

SCILEX is committed to harnessing the power of revolutionary delivery technologies designed to safely and effectively provide therapies to patients who need them the most.

Our pipeline product candidates are

(i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA™”), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain;
(ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido®, has recently completed a Phase 2 trial in acute lower back pain ;

Scilex Pharmaceuticals and Semnur Pharmaceuticals are wholly-owned subsidiaries of Scilex Holding Company.

Section iconCompany Overview

Phone number
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2019
Employees
51-200

Section iconFunding & Financials

  • $25M$50M

    Scilex Pharmaceuticals's revenue is estimated to be in the range of $25M$50M

Section iconFunding & Financials

  • $25M$50M

    Scilex Pharmaceuticals's revenue is estimated to be in the range of $25M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.